Q-omics provides the consensus-scored ARHGDIG profile across patient tissues and cancer cell-line models. ARHGDIG expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARHGDIG is differentially expressed in 12, with the highest sampling consensus in UCEC. Additionally, ARHGDIG RNA expression shows 18,216 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, UCEC, and GBM as cancer lineages where ARHGDIG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGDIG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGDIG survival associations across molecular data types. ARHGDIG RNA expression shows survival associations in the most cancer types (24), followed by mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGDIG RNA expression–survival associations across cancer types. High ARHGDIG expression shows unfavorable associations in KIRC, UVM, ACC, KIRP and BLCA, but favorable associations in LGG. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ARHGDIG RNA expression.
This table summarizes ARHGDIG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12. The strongest signals are observed in UCEC for RNA.
This table ranks reproducible tumor–normal expression differences for ARHGDIG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGDIG shows lower tumor expression in BRCA and HNSC and higher tumor expression in UCEC, COAD, PRAD and THCA. The UCEC box plot shows higher ARHGDIG RNA expression in tumor versus normal tissue (log2 FC = +0.692, t-test p = .008).
This table shows molecular features associated with ARHGDIG in patient tissues and cancer cell lines. In patient samples, ARHGDIG shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGDIG RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BREAST and LARGE_INTESTINE.
